Correlation Between Neurocrine Biosciences and Milestone Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Neurocrine Biosciences and Milestone Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Neurocrine Biosciences and Milestone Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Neurocrine Biosciences and Milestone Pharmaceuticals, you can compare the effects of market volatilities on Neurocrine Biosciences and Milestone Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Neurocrine Biosciences with a short position of Milestone Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Neurocrine Biosciences and Milestone Pharmaceuticals.

Diversification Opportunities for Neurocrine Biosciences and Milestone Pharmaceuticals

-0.19

Correlation Coefficient

Neurocrine Biosciences  Milestone Pharmaceuticals

Good diversification

The 3 months correlation between Neurocrine and Milestone is -0.19. Overlapping area represents the amount of risk that can be diversified away by holding Neurocrine Biosciences and Milestone Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Milestone Pharmaceuticals and Neurocrine Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Neurocrine Biosciences are associated (or correlated) with Milestone Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Milestone Pharmaceuticals has no effect on the direction of Neurocrine Biosciences i.e., Neurocrine Biosciences and Milestone Pharmaceuticals go up and down completely randomly.

Pair Corralation between Neurocrine Biosciences and Milestone Pharmaceuticals

Given the investment horizon of 90 days Neurocrine Biosciences is expected to under-perform the Milestone Pharmaceuticals. In addition to that, Neurocrine Biosciences is 1.92 times more volatile than Milestone Pharmaceuticals. It trades about -0.27 of its total potential returns per unit of risk. Milestone Pharmaceuticals is currently generating about 0.07 per unit of volatility. If you would invest  150.00  in Milestone Pharmaceuticals on June 26, 2024 and sell it today you would earn a total of  4.00  from holding Milestone Pharmaceuticals or generate 2.67% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Neurocrine Biosciences  vs.  Milestone Pharmaceuticals

Neurocrine Biosciences

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Neurocrine Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's forward indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Milestone Pharmaceuticals

Risk-Adjusted Performance

7 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Milestone Pharmaceuticals are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Milestone Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Neurocrine Biosciences and Milestone Pharmaceuticals

The main advantage of trading using opposite Neurocrine Biosciences and Milestone Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Neurocrine Biosciences position performs unexpectedly, Milestone Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Milestone Pharmaceuticals will offset losses from the drop in Milestone Pharmaceuticals' long position.

The idea behind Neurocrine Biosciences and Milestone Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.